CBX-12

CBX-12 is a PDC (peptide drug conjugate) that targets tumors in an antigen-independent manner and exhibits antitumor activity. CBX-12 consists of a pH-sensitive peptide (pHLIP), a self-immolating linker, and a topoisomerase 1 (TOP1) inhibitor Exatecan (HY-13631)[1].

O=C1[C@](O)(CC)C2=C(CO1)C(N3CC4=C5C6=C(CC[C@@H]5NC(OC(C)C(SSC[C@@H](C(O)=O)NC([C@H](CC7=CNC8=CC=CC=C78)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H]([C@H](O)C)NC([C@H](CC(O)=O)NC([C@H]9N(C([C@H](CC%10=CC=CC=C%10)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC([C@H](CC(O)=O)NC([C@H](CC(C)C)NC([C@H](CC%11=CC=C(C=C%11)O)NC([C@H](C)NC([C@H](CCCNC(N)=N)NC([C@H](CCC(O)=O)NC([C@H]%12N(C([C@H](CC(N)=O)NC([C@H](CCC(N)=O)NC([C@H](CC(O)=O)NC([C@H](CC(O)=O)NC([C@H](C)N)=O)=O)=O)=O)=O)CCC%12)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CCC9)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C)=O)C(C)=C(F)C=C6N=C4C3=C2)=O

[1]Rodriguez Rivera I I, et al. CBX-12-101: A first-in-human study of CBX-12, an alphalex peptide drug conjugate (PDC) in patients (pts) with advanced or metastatic solid tumors[J]. 2023.